Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 569.40 |
---|---|
High | 569.40 |
Low | 569.40 |
Bid | 577.00 |
Offer | 577.20 |
Previous close | 560.20 |
Average volume | 115.56 |
---|---|
Shares outstanding | 59.80m |
Free float | 59.72m |
P/E (TTM) | -- |
Market cap | 34.00bn EUR |
EPS (TTM) | -0.802 EUR |
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
- argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
- argenx to Participate at Upcoming Investor Conferences
- argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
- argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
- argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
- argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
More ▼